RecruitingNCT07175285
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Prospective, Observational Study in Participants With Active Systemic Lupus Erythematosus (SLE) (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and At Least 2 Immunosuppressants
Sponsor
Bristol-Myers Squibb
Enrollment
223 participants
Start Date
Oct 8, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants
Eligibility
Min Age: 16 Years
Inclusion Criteria8
- Participants must have signed and dated an Institutional Review Board/ Independent Ethics Committee (IRB/IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines
- Participants must be ≥16 years of age at the time of signing the ICF
- Meet the European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus (SLE)
- Have an inadequate response to glucocorticoids and ≥ 2 immunosuppressant therapies, one of which is a biologic therapy consistent with treatment guidelines, used for at least 3 months each. Eligibility is regardless of prior hydroxychloroquine or any anti-malarial treatment. Inadequate response is defined as a lack of response, insufficient response, or lack of sustained response after at least 3-month treatment with appropriate doses of a standard of care agent. Intolerance or contraindication may be considered as inadequate response provided it is documented and confirmed acceptable by the Adjudication Committee
- Have active disease at study entry when signing ICF, defined as:
- ≥ 1 British Isles Lupus Assessment Group Index (BILAG) A OR ≥ 1 BILAG B with history of SLE manifestations that would qualify for a BILAG A within the last 24 months, AND
- Positive autoantibodies (at least one) to confirm diagnosis of SLE: Antinuclear antibody ≥1:160, anti-dsDNA, anti-Sm, anti-Ro (SSA), anti-La (SSB), or low complement proteins (C3 or C4)
- Participants with lupus nephritis (LN) meeting the study eligibility criteria must have had a renal biopsy per standard of care within 6 months (± 30 days) prior to signing the ICF, indicating the presence of active Class III or IV LN (alone or in combination with Class V) according to the 2018 Revised International Society of Nephrology/Renal Pathology Society (ISN/RPS), with < 60% interstitial fibrosis and tubular atrophy < 60% global glomerulosclerosis
Exclusion Criteria3
- Pregnant women
- Participants enrolled in concurrent interventional clinical trials involving investigational therapies or any other clinical trial
- Participant is unwilling or unable to comply with routine clinical follow-up necessary for collection of study data
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCurrent standard of care treatment options
According to the product label
Locations(58)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07175285
Related Trials
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT073324815 locations
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
NCT070856761 location
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT0630897818 locations
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
NCT055671981 location
Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus
NCT074257301 location